Jerry Gurwitz to United States Food and Drug Administration
This is a "connection" page, showing publications Jerry Gurwitz has written about United States Food and Drug Administration.
Connection Strength
0.555
-
Toh S, Avorn J, D'Agostino RB, Gurwitz JH, Psaty BM, Rothman KJ, Saag KG, Sturkenboom MC, Vandenbroucke JP, Winterstein AG, Strom BL. RE: Drug risk assessment and data reuse. Pharmacoepidemiol Drug Saf. 2014 Jan; 23(1):109-10.
Score: 0.104
-
Toh S, Avorn J, D'Agostino RB, Gurwitz JH, Psaty BM, Rothman KJ, Saag KG, Sturkenboom MC, Vandenbroucke JP, Winterstein AG, Strom BL. Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf. 2013 Oct; 22(10):1036-45.
Score: 0.101
-
Briesacher BA, Soumerai SB, Zhang F, Toh S, Andrade SE, Wagner JL, Shoaibi A, Gurwitz JH. A critical review of methods to evaluate the impact of FDA regulatory actions. Pharmacoepidemiol Drug Saf. 2013 Sep; 22(9):986-94.
Score: 0.101
-
Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, Ng D, Butler MG, Boudreau D, Forrow S, Goldberg R, Gore J, McManus D, Racoosin JA, Gurwitz JH. Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program. Pharmacoepidemiol Drug Saf. 2013 Jan; 22(1):40-54.
Score: 0.094
-
Cutrona SL, Toh S, Iyer A, Foy S, Cavagnaro E, Forrow S, Racoosin JA, Goldberg R, Gurwitz JH. Design for validation of acute myocardial infarction cases in Mini-Sentinel. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:274-81.
Score: 0.091
-
Gurwitz JH. Testing medications in children. N Engl J Med. 2003 Feb 20; 348(8):763-4; author reply 763-4.
Score: 0.049
-
Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf. 2006 Jun; 15(6):369-86.
Score: 0.015